Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (94564)	2/21/2002 9:44:52 AM
From: JHP	Respond to of 132070

LOL Dr. Folkman is talking WHEN not IF! investor.entremed.com Dr. Folkman's presentation will be audio only. lasts about 30 minutes. Event Date Format Entremend Investor Meeting 2/19/2002 HTML Entire event: Entremend Investor Meeting (180 min.)

To: Knighty Tin who wrote (94564)	2/21/2002 11:08:04 AM
From: Knighty Tin	Respond to of 132070

To All, The Wall St. Urinal had its six month stock picking contest. One of our favorites, Joe Battipaglia, undistinguished himself. He was down 8.8%. The dartboard was down 3.8%. Readers were down 1.7%. The Dow was down 5.2%. So, why do folks listen to the guy? He actually finished second out of four, and the two below him were really awful. Now we know why Wall Street always talks about relative rather than absolute performance. <g>

To: Knighty Tin who wrote (94564)	2/21/2002 1:09:24 PM
From: JHP	Respond to of 132070

<<, I wouldn't talk in public about being nimble with goats>> LOL Thursday February 21, 11:33 am Eastern Time Genzyme Transqenics Seeks Two More Partnerships This Year By: Beth Mantz, Of DOW JONES NEWSWIRES NEW YORK (Dow Jones) Genzyme Transgenics Corp. (GZTC) expects to sign two additional partnerships this year, said Chairman and Chief Executive Geoffrey Cox. At the Biotechnology Industry Organization's fourth annual CEO and Investor Conference Thursday, Cox said the biotechnology company now has a number of partnerships. They include projects with Bristol -Myers Squibb Co . (BMY), Elan Corp. (ELN) and Johnson & Johnson's (JNJ) Centocor unit. Genzyme Transgenics expects to produce for its partners large quantities of human proteins as well as animals that have been genetically engineerADVERTISEMENT ed to make the proteins in their milk. For example, genetically-engineered goats would help make the rheumatoid arthritis drug, Remicade, for Centocor. The goats are also helping produce a multiple sclerosis treatment for Elan and a rheumatoid arthritis compound for Bristol -Myers. Genzyme is also developing products on its own. It is working on a protein that would expand an individual's blood supply in acute situations and is trying to develop a human protein that could be used in a malaria vaccine. If the studies on the malaria vaccine show promise, Cox said the company would need a major marketing partner for the vaccine. Genzyme's third internal project is producing a human protein that regulates blood clotting. The company expects results in the third quarter from a trial looking at the drug's process in the body. If the trial is successful, the protein will advance by the end of the year to efficacy trials in patients with a hereditary deficiency. Genzyme may seek marketing approval for the drug in 2004, but the company is seeking to get a partner for the blood-clotting protein this year, Cox said. At the end of 2001, Genzyme had $90.4 million in cash. With an expected cash burn rate of $25 million this year, the company has sufficient financial resources to achieve its goals, said Cox. -By Beth Mantz, Dow Jones Newswires; 201-938-5287 (This story was originally published by Dow Jones Newswires) Copyright (c) 2002 Dow Jones & Company, Inc. All Rights Reserved Email this story - Most-emailed articles - Most-viewed articles -------------------------------------------------------------------------------- More Quotes and News: Bristol-Myers Squibb Co (NYSE:BMY - news) Elan Corporation PLC (NYSE:ELN - news) Genzyme Transgenics Corp (NasdaqNM:GZTC - news) Johnson & Johnson Inc (NYSE:JNJ - news) --------------------------------------------------------------------------------